AGN : Analysis & Opinions

  1. Actavis to Buy Auden Mckenzie, Boost Generic Portfolio - Analyst ...

    January 27, 2015
    Actavis' (ACT) upcoming acquisition of Auden Mckenzie will vault its position to #1 in UK generics.
  2. Roche to Acquire French Biotechnology Company Trophos - Analyst ...

    January 19, 2015
    Roche (RHHBY) announced today that will acquire privately-held French biotechnology company Trophos.
  3. Hospira Submits Retacrit Regulatory Application to the FDA - ...

    January 16, 2015
    Hospira, Inc. (HSP) announced that it has submitted a Biologics License Application looking to get Retacrit approved in the ...
  4. AstraZeneca Announces Encouraging Data from Brilinta Study - ...

    January 15, 2015
    AstraZeneca (AZN) announced encouraging top-line results from the PEGASUS-TIMI 54 study on Brilinta.
  5. Roche to Acquire Up to 56% Interest in Foundation Medicine - ...

    January 14, 2015
    Oncology major, Roche (RHHBY) recently announced that it has entered into a strategic collaboration agreement to acquire ...
  6. Eli Lilly Inks Oncology Deals with Merck, Bristol-Myers - Analyst ...

    January 14, 2015
    Eli Lilly and Company (LLY) has entered into separate agreements with Merck and Bristol-Myers Squibb Company to evaluate ...
  7. Actavis' Q4 Earnings to Beat Expectations, Growth Continues - ...

    January 13, 2015
    Actavis (ACT) expects fourth quarter 2014 earnings to beat Wall Street consensus estimates; the Allergan acquisition is expected ...
  8. Novartis Submits NDA for Ultibro & Seebri Breezhaler - Analyst ...

    January 12, 2015
    Novartis (NVS) recently announced positive top-line results from phase III trials on chronic obstructive pulmonary disease ...
  9. Novartis' Biosimilar of Neupogen Gets Favorable Opinion - Analyst ...

    January 8, 2015
    Novartis' (NVS) generic arm, Sandoz, announced that the U.S. Food and Drug Administration's (FDA) Oncologic Drugs Advisory ...
  10. Pfizer Boosts Vaccine Pipeline with Redvax Acquisition - Analyst ...

    January 7, 2015
    Pfizer's (PFE) acquisition of Redvax makes the company one of the leaders in CMV research and development.
  11. Roche Collaborates with 23andMe for Parkinson's Disease - Analyst ...

    January 7, 2015
    Roche (RHHBY) and personal genetics company 23andMe, Inc. announced an agreement to make breakthroughs in therapeutic research ...
  12. Pharmacyclics Reports Encouraging Data on Cancer Drug - Analyst ...

    January 6, 2015
    Pharmacyclics, Inc. (PCYC) announced encouraging data on its oncology drug, Imbruvica.
  13. Teva's Granix Label Expanded to Include Self-Administration - ...

    December 30, 2014
    Teva Pharmaceutical Industries Ltd. (TEVA) announced that an additional administration option for Granix injection has been ...
  14. Gilead/J&J Expand TAF-based HIV Drugs Related Agreement - Analyst ...

    December 30, 2014
    Gilead Sciences, Inc. announced that it has expanded its agreement with Janssen R&D Ireland, a subsidiary of Johnson ...
  15. Roche's Ebola Test Gets FDA's Emergency Use Authorization - Analyst ...

    December 30, 2014
    Roche (RHHBY) announced that the FDA has granted Emergency Use Authorization for the LightMix Ebola Zaire rRT-PCR Test.
  16. Novartis' Cosentyx Approved in Japan for Psoriatic Arthritis ...

    December 29, 2014
    Novartis (NVS) announced that the Japanese Ministry of Health, Labour and Welfare has approved Cosentyx (secukinumab) for ...
  17. Novartis' Alcon's Travatan Obtains Label Expansion in the EU ...

    December 26, 2014
    Novartis AG (NVS) recently announced that its ophthalmology arm Alcon was granted a label expansion by the European Commission ...
  18. Roche' (RHHBY) Blood Cancer Drug Gazyva's Label Updated - Analyst ...

    December 26, 2014
    Roche (RHHBY) announced that the FDA has approved a supplemental biologics license application (sBLA) for its blood cancer ...
  19. Pharmacyclics Reveals FDA Action Date for Imbruvica sNDA - Analyst ...

    December 23, 2014
    Pharmacyclics, Inc. (PCYC) announced that the FDA is expected to render a final opinion on the supplemental New Drug Application ...
  20. Bristol-Myers Oncology Drug Opdivo Receives FDA Approval - Analyst ...

    December 23, 2014
    Bristol-Myers Squibb Company announced that the FDA has cleared its intravenous human programmed death receptor-1 blocking ...
  21. Keryx (KERX) Launches Renal Drug Auryxia in the U.S. - Analyst ...

    December 23, 2014
    Keryx Biopharmaceuticals, Inc. (KERX) announced it has begun to ship Auryxia (ferric citrate) tablets to wholesalers in the ...
  22. Actavis' Antibiotic a Step Closer to EU Nod, CHMP Positive - ...

    December 22, 2014
    Actavis' (ACT) antibiotic, Xydalba, which is already marketed in the U.S. under the trade name Dalvance, is a step closer ...
  23. AstraZeneca's Lynparza Cleared in U.S. for Ovarian Cancer - Analyst ...

    December 22, 2014
    The FDA has cleared AstraZeneca's (AZN) Lynparza as a monotherapy for the maintenance treatment of adults suffering from ...
  24. Roche to Acquire Austrian Biotechnology Company Dutalys - Analyst ...

    December 22, 2014
    Roche (RHHBY) recently announced it has agreed to acquire a privately-held Austrian biotechnology company named Dutalys GmbH.
  25. Novo Nordisk's Tresiba Favored by CHMP for Expanded Use - Analyst ...

    December 22, 2014
    Novo Nordisk (NVO) announced that the Committee for Medicinal Products for Human Use (CHMP) has recommended Tresiba for expanded ...
  26. Allergan, Inc. (AGN): New Analyst Report from Zacks Equity Research ...

    December 22, 2014
    Allergan posted better-than-expected third quarter earnings of $1.78 per share, surpassing the Zacks Consensus Estimate of ...
  27. Merck Up on OncoEthix Acquisition Deal, Oncology in Focus - Analyst ...

    December 19, 2014
    Merck (MRK) acquired Swiss biotech privately held company, OncoEthix, and added a promising experimental early-stage candidate, ...
  28. AstraZeneca's Lynparza Approved in EU for Ovarian Cancer - Analyst ...

    December 19, 2014
    AstraZeneca's (AZN) Lynparza was approved as a monotherapy for the maintenance treatment of adults suffering from ovarian ...
  29. Novartis Successfully Expands Signifor Label in the U.S. - Analyst ...

    December 17, 2014
    Novartis's (NVS) Signifor long-acting release was approved in the U.S. for the acromegaly indication.
  30. 3 U.S. Medical Devices Stocks That Surged in 2014 - Analyst Blog

    December 17, 2014
    The prospects of the medical devices industry have improved following a Republican victory in the midterm elections.
  31. This ETF Offers Easy Access To Big Pharma

    November 21, 2014
    Pharma investing isn't for everyone, but sector-specific ETFs, such as the iShares Dow Jones U.S. Pharmaceuticals ETF, have ...
  32. Pharma Industry Outlook: M&A, Licensing Abound - Industry Outlook

    November 18, 2014
    Pharma Industry Outlook: M&A, Licensing Abound - Industry Outlook
  33. All Quiet On The Market Front: Dow, S&P 500, Nasdaq Virtually ...

    November 12, 2014
  34. Pharma, Biotech M&As Heat Up: Tax Inversion in Focus - Industry ...

    July 24, 2014
    Pharma, Biotech M&As Heat Up: Tax Inversion in Focus - Industry Outlook
  35. Learn How To Invest Defensively From This Hedge Fund Pro

    May 21, 2014
    With the Dow Jones Industrial Average and the S&P 500 hovering near all-time highs and plenty of investors shifting to a ...
  36. Technical Outlook For Four Exceptionally Hot Stocks

    January 15, 2014
    These four large cap stocks are all up more than 30% in the last three months. Here's the technical outlook going forward.
  37. Yet Another Failure Has Rigel Pharmaceuticals Almost Back To ...

    August 26, 2013
    Rigel sees yet another clinical failure from its pipeline.
  38. After A Sharp Pullback, Is Allergan Pretty Enough?

    July 31, 2013
    Down on fears about generics and the pipeline, the Street may be underestimating Allergan
  39. Valeant Eyes Bausch & Lomb

    May 28, 2013
    Canadian pharmaceutical company Valeant has made a name for itself through acquisitions. On May 27 it announced that it was ...
  40. Abbott Spins Off Pharma Business - Analyst Blog

    January 3, 2013
    Abbott Laboratories (ABT) recently announced that the company has separated its research-based pharmaceuticals business by ...
  41. Allergan Third Quarter Earnings

    October 30, 2012
    Allergan (NYSE:AGN) announced its results for the most recent quarter on October 30, 2012. Allergan is a global specialty ...
  42. Valeant Works Its Mojo With Medicis

    September 7, 2012
    Valeant makes a bold but logical bid for Medicis.
  43. Allergan and Other NYSE Stocks Making Big Moves

    August 1, 2012
    After this morning's trading, the market is looking good. The Nasdaq has increased 0.1%; the S&P 500 is trading up 0.5%; ...
  44. Obagi Puts Its Problems Behind It

    May 25, 2012
    A year ago, Obagi Medical Products faced some problems in Texas that presented an investment opportunity. One year later ...
  45. 6 Overbought Stocks To Watch

    March 30, 2012
    Let's take a look at a few stocks that have recently entered overbought territory because these could be candidates for a ...
  46. Top Drug Stocks

    June 30, 2011
    Recently, three strong factors are driving investors to the drug sector.
  47. Obagi's Pitfalls Provide Investment Opportunity

    May 24, 2011
    Obagi's stock dropped 24% after announcing a 13-cent loss in its first quarter. Find out why this presents an opportunity ...
  48. Novartis Brings Alcon Into The Fold

    December 16, 2010
    Novartis closes the deal for Alcon.
  49. Allergan Winning Wall Street's Beauty Pageant

    November 3, 2010
    Allergan's earnings aren't special, but the stock is basking in Wall Street's love. Is it simply a case of lipstick on a ...
  50. Novartis Looks For 20/20 Vision With Alcon

    January 11, 2010
    The Swiss drug maker hopes to take full ownership of Alcon later in the year. Find out what it'll mean for these two companies.
Trading Center